Kenvue Inc. (NYSE:KVUE) Shares Sold by Easterly Investment Partners LLC

Easterly Investment Partners LLC trimmed its position in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 74.4% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 148,991 shares of the company's stock after selling 433,345 shares during the quarter. Easterly Investment Partners LLC's holdings in Kenvue were worth $3,446,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently bought and sold shares of the company. Leo Wealth LLC raised its stake in Kenvue by 0.3% during the 3rd quarter. Leo Wealth LLC now owns 151,611 shares of the company's stock worth $3,507,000 after buying an additional 481 shares during the period. Massmutual Trust Co. FSB ADV raised its position in shares of Kenvue by 6.2% during the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 8,400 shares of the company's stock worth $194,000 after acquiring an additional 492 shares in the last quarter. Wolff Wiese Magana LLC raised its holdings in Kenvue by 0.7% during the third quarter. Wolff Wiese Magana LLC now owns 76,999 shares of the company's stock worth $1,781,000 after purchasing an additional 501 shares in the last quarter. Marathon Capital Management grew its stake in Kenvue by 0.3% during the 2nd quarter. Marathon Capital Management now owns 149,699 shares of the company's stock valued at $2,722,000 after purchasing an additional 514 shares in the last quarter. Finally, Manchester Capital Management LLC lifted its stake in shares of Kenvue by 80.8% in the first quarter. Manchester Capital Management LLC now owns 1,186 shares of the company's stock worth $25,000 after buying an additional 530 shares during the last quarter. Institutional investors own 97.64% of the company's stock.

Kenvue Stock Up 3.1 %

NYSE:KVUE traded up $0.72 during trading hours on Friday, reaching $23.69. 16,635,102 shares of the company traded hands, compared to its average volume of 18,141,881. The company has a current ratio of 0.99, a quick ratio of 0.68 and a debt-to-equity ratio of 0.69. The business's 50-day moving average price is $22.65 and its two-hundred day moving average price is $20.53. The stock has a market capitalization of $45.37 billion, a P/E ratio of 43.07, a P/E/G ratio of 3.01 and a beta of 1.36. Kenvue Inc. has a 1 year low of $17.67 and a 1 year high of $23.72.

Kenvue (NYSE:KVUE - Get Free Report) last posted its earnings results on Thursday, November 7th. The company reported $0.28 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.27 by $0.01. Kenvue had a return on equity of 21.80% and a net margin of 7.23%. The business had revenue of $3.90 billion during the quarter, compared to analysts' expectations of $3.92 billion. During the same period in the prior year, the business earned $0.31 EPS. Kenvue's revenue for the quarter was down .4% compared to the same quarter last year. Analysts predict that Kenvue Inc. will post 1.08 earnings per share for the current year.

Kenvue Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, November 27th. Investors of record on Wednesday, November 13th will be paid a $0.205 dividend. The ex-dividend date of this dividend is Wednesday, November 13th. This represents a $0.82 dividend on an annualized basis and a yield of 3.46%. Kenvue's dividend payout ratio is currently 149.09%.

Wall Street Analyst Weigh In

A number of research firms have weighed in on KVUE. UBS Group upped their price objective on shares of Kenvue from $20.00 to $22.00 and gave the company a "neutral" rating in a report on Wednesday, August 7th. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Kenvue from $23.00 to $24.00 and gave the company a "buy" rating in a research report on Wednesday, August 7th. Royal Bank of Canada cut shares of Kenvue from an "outperform" rating to a "sector perform" rating and set a $24.00 target price on the stock. in a research report on Tuesday, September 24th. JPMorgan Chase & Co. raised their target price on shares of Kenvue from $24.00 to $25.00 and gave the stock an "overweight" rating in a research report on Friday, October 11th. Finally, Piper Sandler lifted their target price on Kenvue from $20.00 to $21.00 and gave the company a "neutral" rating in a research report on Monday, September 23rd. One analyst has rated the stock with a sell rating, seven have given a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, Kenvue has an average rating of "Hold" and a consensus price target of $22.64.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.